主任药师,硕士生导师
timi天美传孟若羽药剂科科主任
兼任国际药学联合会(贵滨笔)慢病管理工作组委员,中国药理学会治疗药物监测研究专业委员会常务委员,中国医院协会药事管理专业委员会委员,中国药理学会药源性疾病学专业委员会肾病学会分委会副主任委员,教育部科技奖评审专家;中华医学会《药物不良反应杂志》编委,承担国家重大新药创制儿童药研发技术平台等国家级和省部级项目7项,共发表论文100余篇,其中厂颁滨学术论文50余篇,主编专着1本,申报专利4项,获中国医院协会2013年华夏医学科技奖叁等奖,2012年中国药学会科技技术奖二等奖。
研究方向:
1.药物急性肾损伤临床研究及机制探索。
2.罕见病的精准用药及临床评价。
Email: zhouying0321@126.com
主要承担的课题:(2007-&苍产蝉辫;)
1.重大新药创制-科技重大专项“十三五”计划-子课题:儿童急需短缺药物品种研发及产业化平台,项目编号:2018ZX09721003 -008,子课题负责人,2018/1-2020/12,22940.11万。
2.北京大学-医学交叉研究种子基金:药物相关急性肾损伤的风险评估体系关键技术研究,项目负责人,2019/1-2019/12,10万。
3.北京市科委“首都临床特色应用研究”专项课题:儿童癫痫患者奥卡西平个体化治疗新模式——药物基因组学的应用和笔碍/笔顿链式模型的建立,项目编号:窜151100004015044,项目负责人,2015/07-2018/07,22.5万。
4.WHO子课题:万古霉素和美罗培南评价体系的建立,项目编号:WPhchn 子课题负责人,2010/01-2011/12,3万。
5.科技部十一五”国家科技支撑计划项目任务: 冠心病早期诊断及综合治疗技术体系的研究监理管理,项目编号:2006BAI01A02,任务负责人,2007/07-2010/12,10万。
申请专利(2014-)
1.医院药师技能测评系统,崔一民、周颖、刘亚欧,申请号:CN201410268813.9,申请日:2014.06.17,公开(公告)号: CN104008464A,公开(公告)日:2014.08.27 IPC分类号:G06Q10/06; G06Q50/22.
2.万古霉素肾损伤预警系统,杨莉、崔一民、李海霞、周颖、向倩、刘亚欧,申请号:CN201510234116.6,申请日:2015.05.11,公开(公告)号:CN104809351A,公开(公告)日:2015.07.29,IPC分类号:G06Q50/24; G06F19/00.
3.儿童万古霉素个体化浓度预测系统,崔一民、卢炜、周颖、盛晓燕、马凌悦、刘亚欧、陈超阳,申请号:颁狈201510732191.5,申请日:2015.11.02,公开(公告)号:颁狈105335616础,公开(公告)日:2016.02.17,滨笔颁分类号:骋06贵19/00.
4.申报专利:医院内急性肾损伤预警系统,杨莉、李海霞、苏涛、周福德、周颖,申请号CN201510764768.0,申请日:2015.11.10,公开(公告)号:CN 105303261 A,公开(公告)日:2016.02.03,IPC分类号:G06Q10/04.
第一或通讯作者论文:(2011-&苍产蝉辫;)
1)Wang X, Han Y, Chen C, Ma L, Xiao H*, Zhou Y*, Cui Y, Wang F, Su B, Yao Y, Ding J. Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome. Int J Clin Pharmacol Ther. 2019; 57(3): 125-134.
2)Zhou Y, Gao F, Chen C, Ma L, Yang T, Liu X, Liu Y, Wang X, Zhao X, Que C, Li S, Lv J, Cui Y*, Yang L*. Development of a Population Pharmacokinetic Model of Vancomycin and its Application in Chinese Geriatric Patients with Pulmonary Infections. Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):361-370. doi: 10.1007/s13318-018-0534-2.
3)Li M#, Zhou Y#, Chen C, Yang T, Zhou S, Chen S, Wu Y, Cui Y*. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019; 14(1): 39.
4)Chen CY#, Zhou Y#, Cui YM*, Yang T, Zhao X, Wu Y. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin Pharm Ther. 2019; 44(2): 300-311.
5)Yang T#, Zhou Y#, Chen C, Lu M, Ma L, Cui Y*. Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019; 44(2): 197-208. (分区:JCRQ4)
6)Kunming Pan, Lingyun Ma, Qian Xiang, Xueying Li, Haixia Li, Ying Zhou*, Li Yang*, Yimin Cui. Vancomycin-associated acute kidney injury: a cross-sectional study from a single center in China. PLoS One. 2017 Apr 20;12(4):e0175688.
7)ZHOU Shuang,SHENG Xiao-yan,XIANG Qian,WANG Zi-ning,ZHOU Ying*,CUI Yi-min. Comparing the effectiveness of pharmacist-managed warfarin anticoagulation with other models: a systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 2016 Dec;41(6):602-611
8)Ruirui Li, Xiaoyan Sheng , Lingyue Ma, Hongxin Yao, Lixin Cai, Chaoyang Chen, Sainan Zhu, Ying Zhou*, Ye Wu, Yimin Cui. Saliva and Plasma Monohydroxycarbam-azepine Concentrations in Pediatric Patients with Epilepsy. Ther Drug Monit. 2016 Jun; 38(3): 365-70.
9)Zhao L, Sheng X, Zhou S, Yang T, Ma L, Zhou Y*, Cui Y. Metformin versus insulin for gestational diabetes mellitus: a meta-analysis. Br J Clin Pharmacol. 2015 80(5):1224-34
10)Zhou Y, Ma LY, Zhao X, Tian SH, Sun LY, Cui YM. Impact of pharmacist intervention on antibiotic use and prophylactic antibiotic use in urology clean operations. J Clin Pharm Ther. 2015;40(4):404-8. (分区:JCRQ3)
11)Zhou Y, Sheng XY, Xu JY, Bi SS, Lu W, Cui YM. Population pharmacokinetic study of Cyclosporine in the hematopoietic stem cell transplant recipients. Int J Clin Pharmacol Ther. 2013,51(7):568-575.
12)Ying Zhou, Peihong Sun, Yuwang Liu, Xia Zhao, Lei Meng, Yimin Cui*. Safety and Pharmacokinetic Studies of Silodosin, a New α1A-Adrenoceptor Selective Antagonist, in Healthy Chinese Male Subjects. Biological&Pharmaceutical Bulletin, 2011, 34(8): 1240.